


## グリメピリド (日本薬局方収載原案記載条件; 類縁物質)



疎水性の異なるC18カラムによる比較

U101216A

J'sphere ODS-M80 (標準タイプ C18)



J'sphere ODS-L80 (低疎水性タイプ C18)



	System suitability requirement	result	
		J'sphere ODS-M80	J'sphere ODS-L80
Theoretical plate number (Glimepiride)	9000	24600	21300
Tailing factor (Glimepiride)	1.5	1.04	1.10

Column : 250 X 4.0 mmI.D. (4  $\mu$ m, 8 nm)  
 Eluent : phosphate buffer (pH 2.5)/acetonitrile (50/50)  
*phosphate buffer : dissolve 0.5 g of NaH<sub>2</sub>PO<sub>4</sub> in 500 mL water and adjust pH 2.5 with H<sub>3</sub>PO<sub>4</sub>*  
 Flow rate : *adjust the flow rate so that the retention time of Glimepiride is about 17 min*  
 Temperature : 25  
 Detection : UV at 228 nm  
 Injection : 20  $\mu$ L  
 Sample : Glimepiride\* (0.0002 mg/mL, correspond to standard solution)


\* A reagent for laboratory use

## グリメピリド (日本薬局方収載原案記載条件; 定量法)



疎水性の異なるC18カラムによる比較

U101215A

J'sphere ODS-M80 (標準タイプ C18)



J'sphere ODS-L80 (低疎水性タイプ C18)



	System suitability requirement	result	
		J'sphere ODS-M80	J'sphere ODS-L80
Theoretical plate number (Glimepiride)	≥ 9000	20400	18400
Tailing factor (Glimepiride)	≤ 1.5	0.98	1.12


Column : 250 X 4.0 mmI.D. (4 μm, 8 nm)  
 Eluent : phosphate buffer (pH 2.5)/acetonitrile (50/50)  
*phosphate buffer : dissolve 0.5 g of NaH<sub>2</sub>PO<sub>4</sub> in 500 mL water and adjust pH 2.5 with H<sub>3</sub>PO<sub>4</sub>*  
 Flow rate : *adjust the flow rate so that the retention time of Glimepiride is about 17 min*  
 Temperature : 25°C  
 Detection : UV at 228 nm  
 Injection : 20 μL  
 Sample : Glimepiride\* (0.2 mg/mL, correspond to standard solution)

\* A reagent for laboratory use

グリメピリド錠  
Glimepiride Tablets



U101222A

A) Standard solution\*  
(0.0018 mg/mL Glimepiride)



	System suitability requirement	result
Theoretical plate number (Glimepiride)	$\geq 6000$	9700
Tailing factor (Glimepiride)	$\leq 1.5$	1.02

B) Sample solution\*  
(0.18 mg/mL Glimepiride)



Column : YMC-Triart C18 (5  $\mu$ m, 12 nm)  
125 X 4.0 mmI.D.

Eluent : phosphate buffer (pH 3.5)/acetonitrile (50/50)  
*phosphate buffer : dissolve 0.5 g of NaH<sub>2</sub>PO<sub>4</sub> in 500 mL water and adjust pH 3.5 with H<sub>3</sub>PO<sub>4</sub> (1 $\rightarrow$ 5)*

Flow rate : 0.75 mL/min

Temperature : 25°C

Detection : UV at 228 nm


Injection : 5  $\mu$ L

(The draft for the Japanese Pharmacopoeia; Related substances)


\* All standard and sample solutions were prepared from Glimepiride supplied as a reagent for laboratory use.

グリメピリド錠  
Glimepiride Tablets

U101220A




1



Butyl *p*-hydroxybenzoate (I.S.)

2



Glimepiride

	System suitability requirement	result
Resolution (1, 2)	≥6	12.5

Column : YMC-Triart C18 (5 μm, 12 nm)  
125 X 4.0 mm I.D.

Eluent : phosphate buffer (pH 3.5)/acetonitrile (50/50)  
*phosphate buffer : dissolve 0.5 g of NaH<sub>2</sub>PO<sub>4</sub> in 500 mL water and adjust pH 3.5 with H<sub>3</sub>PO<sub>4</sub> (1→5)*

Flow rate : 0.9 mL/min

Temperature : 25°C

Detection : UV at 228 nm

Injection : 10 μL

Sample : 1. Butyl *p*-hydroxybenzoate (0.12 mg/mL)  
2. Glimepiride\* (0.06 mg/mL)

(The draft for the Japanese Pharmacopoeia; Assay)

\* Glimepiride: A reagent for laboratory use